Welcome to this week's edition of The Targeted Pulse, your clinical-focused wrap-up of the most impactful news and research ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

An MD Anderson team led by Amir Jazaeri, MD, takes a pioneering approach to finding residual ovarian cancer cells.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Robert L. Ferris, MD, PhD, editor-in-chief of Targeted Therapies in Oncology, discusses his monthly column in this episode of ...

A study shows talquetamab is a safe, effective bridge for high-risk patients, potentially improving outcomes and mitigating ...

During a live event, Steven I. Robinson, MBBS, discussed desmoid tumor statistics and management for symptomatic progression.

A new study suggests the MAGIC Composite Response metric, which combines clinical and biomarker data, improves prediction of ...

Emerging treatments for low-grade serous ovarian cancer and platinum-resistant disease offer new hope, with promising data ...

Research reveals innovative methods for detecting minimal residual disease in ovarian cancer, enhancing prognosis and paving ...

Early results from the TUSCANY trial highlight promising remission rates and safety for a new triplet therapy in treating ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...